Rheumatoid arthritis in 2010: From the gut to the joint

Nature Reviews Rheumatology

Volumn 7, Issue 2, 2011, Pages 73-75

  Scheinecker, Clemens ^a   Smolen, Josef S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOSTAMATINIB; GLUCOCORTICOID; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO;

AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY PRODUCTION; ARTHRITIS; AUTOIMMUNITY; CLINICAL RESEARCH; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EARLY DIAGNOSIS; EARLY INTERVENTION; GERMINAL CENTER; HUMAN; INTESTINE FLORA; JOINT DESTRUCTION; MICROBIAL COLONIZATION; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TH17 CELL;

ANIMALS; ARTHRITIS, RHEUMATOID; GLUCOCORTICOIDS; HUMANS; INTESTINES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OXAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TH17 CELLS;

EID: 79551717489     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.226     Document Type: Review

References (10)

1. wu, H.-J. et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32, 815-827 (2010).
2. wegner, n. et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 62, 2662-2672 (2010).
3. Quinn, M. a. et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum. 48, 3039-3045 (2003). (Pubitemid 37409313)
4. Machold, K. P. et al. The Stop arthritis very early (Save) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann. Rheum. Dis. 69, 495-502 (2010).
5. verstappen, S. M. M. et al. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STivea trial. Ann. Rheum. Dis. 69, 503-509 (2010).
6. aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an american College of rheumatology/european League against rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580-1588 (2010).
7. aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an american College of rheumatology/european League against rheumatism collaborative initiative. Arthritis Rheum. 62, 2569-2581 (2010).
8. weinblatt, M. e. et al. an oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303-1312 (2010).
9. Genovese, M. C. et al. an oral syk kinase inhibitor in the treatment of rheumatoid arthritis: a 3 month randomized placebo controlled phase 2 study in patients with active ra who had failed biologic agents. Arthritis Rheum. doi:10.1002/art.30114.
10. Kremer, J. M. et al. The safety and efficacy of a JaK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebocontrolled phase iia trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60, 1895-1905 (2009).